Prognostic role of CD44 expression in osteosarcoma: evidence from six studies

Diagnostic Pathology

Peng Sheng¹  Kelin Xu¹  Haifeng Li¹  Yao Lu¹  Jianbing Wang¹  Yongjun Rui¹  Zhenzhong Sun¹  Sanjun Gu¹  Yongwei Wu¹  Yu Liu¹ 

[1] Department of Orthopedics, The Ninth People's Hospital of Wuxi City, The Affiliated Wuxi Hospital of Soochow University, No.999 Liangxi Road, Wuxi, Jiangsu, Province 214062, China

关键词: Meta-analysis;    Prognosis;    Osteosarcoma;    Bone tumor;    CD44;   

Others  :  1150024
DOI  :  10.1186/1746-1596-9-140

 received in 2014-05-18, accepted in 2014-06-23,  发布年份 2014

【 摘 要 】

Background

Numerous studies examining the relationship between CD44 expression and prognostic impact in patients with osteosarcoma have yielded inconclusive results. The aim of this meta-analysis was carried out to investigate the relationship between CD44 expression and the survival in patients with osteosarcoma.

Methods

We therefore conducted a meta-analysis to provide a comprehensive evaluation of the prognostic role of CD44 expression on the overall survival rate and metastasis, which compared the positive and negative expression of CD44 in patients of the available studies.

Results

A detailed search was made in MEDLINE and EMBASE for relevant original articles published in English. Finally, a total of six studies with 329 osteosarcoma patients were involved to estimate the relationship between CD44 expression and metastasis of tumor and overall survival. Positive expressions of CD44 did not predict neoplasm metastasis (RR = 1.36, 95% CI: 1.00–1.84, P = 0.50), and the results indicated that higher expression of CD44 could not predict poorer survival in osteosarcoma with the pooled HR of 0.55 (95% CI: 0.27–1.13, P = 0.47).

Conclusions

The findings from this present meta-analysis suggest that CD44 expression is not associated with overall survival rate and metastasis in osteosarcoma.

Virtual Slides

The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1373995521295618 webcite

【 授权许可】

   
2014 Liu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Bertucci F, Araujo J, Giovannini M: Pancreatic metastasis from osteosarcoma and Ewing sarcoma: literature review. Scand J Gastroenterol 2013, 48:4-8.
• [2]Kong C, Hansen MF: Biomarkers in Osteosarcoma. Expert Opin Med Diagn 2009, 3:13-23.
• [3]Ottaviani G, Jaffe N: The etiology of osteosarcoma. Cancer Treat Res 2009, 152:15-32.
• [4]Picci P, Mercuri M, Ferrari S, Alberghini M, Briccoli A, Ferrari C, Pignotti E, Bacci G: Survival in high-grade osteosarcoma: improvement over 21 years at a single institution. Ann Oncol 2010, 21:1366-1373.
• [5]Durnali A, Alkis N, Cangur S, Yukruk FA, Inal A, Tokluoglu S, Seker MM, Bal O, Akman T, Inanc M, Isikdogan A, Demirci A, Helvaci K, Oksuzoglu B: Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients. Med Oncol 2013, 30:624.
• [6]Gorlick R: Osteosarcoma: clinical practice and the expanding role of biology. J Musculoskelet Neuronal Interact 2002, 2:549-551.
• [7]Wibulswas A, Croft D, Pitsillides AA, Bacarese-Hamilton I, McIntyre P, Genot E, Kramer IM: Influence of epitopes CD44v3 and CD44v6 in the invasive behavior of fibroblast-like synoviocytes derived from rheumatoid arthritic joints. Arthritis Rheum 2002, 46:2059-2064.
• [8]Fehon RG, McClatchey AI, Bretscher A: Organizing the cell cortex: the role of ERM proteins. Nat Rev Mol Cell Biol 2010, 11:276-287.
• [9]Lamontagne CA, Grandbois M: PKC-induced stiffening of hyaluronan/CD44 linkage; local force measurements on glioma cells. Exp Cell Res 2008, 314:227-236.
• [10]Zhang XG, Lu XF, Jiao XM, Chen B, Wu JX: PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Exp Ther Med 2012, 4:1005-1009.
• [11]Jung T, Gross W, Zoller M: CD44v6 coordinates tumor matrix-triggered motility and apoptosis resistance. J Biol Chem 2011, 286:15862-15874.
• [12]Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, Cheng C: CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011, 121:1064-1074.
• [13]Leung EL, Fiscus RR, Tung JW, Tin VP, Cheng LC, Sihoe AD, Fink LM, Ma Y, Wong MP: Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010, 5:e14062.
• [14]Su YJ, Lai HM, Chang YW, Chen GY, Lee JL: Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J 2011, 30:3186-3199.
• [15]Esteban F, Bravo JJ, Gonzalez-Moles MA, Bravo M, Ruiz-Avila I, Gil-Montoya JA: Adhesion molecule CD44 as a prognostic factor in laryngeal cancer. Anticancer Res 2005, 25:1115-1121.
• [16]Xu YP, Zhao XQ, Sommer K, Moubayed P: Correlation of matrix metalloproteinase-2, -9, tissue inhibitor-1 of matrix metalloproteinase and CD44 variant 6 in head and neck cancer metastasis. J Zhejiang Univ Sci 2003, 4:491-501.
• [17]Bradburn MJ, Deeks JJ, Berlin JA, Russell LA: Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007, 26:53-77.
• [18]Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
• [19]Boldrini E, Peres SV, Morini S, de Camargo B: Immunoexpression of Ezrin and CD44 in patients with osteosarcoma. J Pediatr Hematol Oncol 2010, 32:e213-e217.
• [20]Deng Z, Niu G, Cai L, Wei R, Zhao X: The prognostic significance of CD44V6, CDH11, and beta-catenin expression in patients with osteosarcoma. Biomed Res Int 2013, 2013:496193.
• [21]Gvozdenovic A, Arlt MJ, Campanile C, Brennecke P, Husmann K, Li Y, Born W, Muff R, Fuchs B: CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res 2013, 28:838-847.
• [22]Kim HS, Park YB, Oh JH, Jeong J, Kim CJ, Lee SH: Expression of CD44 isoforms correlates with the metastatic potential of osteosarcoma. Clin Orthop Relat Res 2002, 396:184-190.
• [23]Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H: Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol 1999, 125:646-652.
• [24]Ma Q, Zhou Y, Ma B, Chen X, Wen Y, Liu Y, Fan Q, Qiu X: The clinical value of CXCR4, HER2 and CD44 in human osteosarcoma: A pilot study. Oncol Lett 2012, 3:797-801.
• [25]Siclari VA, Qin L: Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010, 5:78.
• [26]Osborne TS, Khanna C: A review of the association between osteosarcoma metastasis and protein translation. J Comp Pathol 2012, 146:132-142.
• [27]Nakajima G, Patino-Garcia A, Bruheim S, Xi Y, San Julian M, Lecanda F, Sierrasesumaga L, Muller C, Fodstad O, Ju J: CDH11 expression is associated with survival in patients with osteosarcoma. Canc Genomics Proteomics 2008, 5:37-42.
• [28]Nguyen LV, Vanner R, Dirks P, Eaves CJ: Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
• [29]Wang K, Xu J, Zhang J, Huang J: Prognostic role of CD133 expression in colorectal cancer: a meta-analysis. BMC Cancer 2012, 12:573.
• [30]Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, Huang J, Xu AX: Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis. PLoS One 2013, 8:e70958.
• [31]Jamal HH, Aubin JE: CD44 expression in fetal rat bone: in vivo and in vitro analysis. Exp Cell Res 1996, 223:467-477.
• [32]Iwaya K, Ogawa H, Kuroda M, Izumi M, Ishida T, Mukai K: Cytoplasmic and/or nuclear staining of beta-catenin is associated with lung metastasis. Clin Exp Metastasis 2003, 20:525-529.
• [33]Song B, Wang Y, Titmus MA, Botchkina G, Formentini A, Kornmann M, Ju J: Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells. Mol Cancer 2010, 9:96.
• [34]Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J: Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells. Oncogene 2009, 28:4065-4074.
• [35]Zhao H, Ma B, Wang Y, Han T, Zheng L, Sun C, Liu T, Zhang Y, Qiu X, Fan Q: miR-34a inhibits the metastasis of osteosarcoma cells by repressing the expression of CD44. Oncol Rep 2013, 29:1027-1036.
• [36]Zhu H, Tang J, Tang M, Cai H: Upregulation of SOX9 in osteosarcoma and its association with tumor progression and patients' prognosis. Diagn Pathol 2013, 8:183.
• [37]Nada OH, Ahmed NS, Abou Gabal HH: Prognostic significance of HLA EMR8-5 immunohistochemically analyzed expression in osteosarcoma. Diagn Pathol 2014, 9:72.